New Data Support Boost in ER-/HER2- Breast Cancer

At ESTRO 2025, Anders Winther Mølby Nielsen, MD, PhD student at Aarhus University, presented a post-hoc analysis from the DBCG IMN2 study. The findings show that older breast cancer patients with ER-negative/HER2-negative tumors had a notably higher risk of local recurrence when treated without a tumor bed boost. Based on these results, Danish guidelines now recommend boost radiation for this subgroup, regardless of age.